Arcellx, Inc. Files Q1 2025 10-Q Report
Ticker: ACLX · Form: 10-Q · Filed: May 8, 2025 · CIK: 1786205
| Field | Detail |
|---|---|
| Company | Arcellx, INC. (ACLX) |
| Form Type | 10-Q |
| Filed Date | May 8, 2025 |
| Risk Level | medium |
| Sentiment | neutral |
Sentiment: neutral
Topics: 10-Q, financials, biotechnology
TL;DR
Arcellx Q1 10-Q filed. Financials and ops update.
AI Summary
Arcellx, Inc. filed its 10-Q for the period ending March 31, 2025. The company reported its financial results and provided updates on its business operations. Key financial data and operational highlights are detailed within the filing.
Why It Matters
This filing provides investors with a quarterly update on Arcellx's financial health and strategic progress, crucial for understanding the company's performance in the biotechnology sector.
Risk Assessment
Risk Level: medium — As a biotechnology company, Arcellx faces inherent risks related to drug development, regulatory approvals, and market competition.
Key Numbers
- 2025-03-31 — Reporting Period End Date (Indicates the end of the fiscal quarter for which financial data is reported.)
- 2025-05-08 — Filing Date (The date the 10-Q report was officially submitted to the SEC.)
Key Players & Entities
- Arcellx, Inc. (company) — Filer of the 10-Q report
- Gilead (company) — Mentioned in collaboration agreements
- Kite Pharma, Inc. (company) — Mentioned in collaboration agreements
FAQ
What is the reporting period for this 10-Q filing?
The reporting period for this 10-Q filing is March 31, 2025.
When was this 10-Q filed with the SEC?
This 10-Q was filed on May 8, 2025.
What is the company's Central Index Key (CIK)?
The company's Central Index Key (CIK) is 0001786205.
What is Arcellx, Inc.'s Standard Industrial Classification (SIC) code?
Arcellx, Inc.'s Standard Industrial Classification (SIC) code is 2836, for Biological Products (No Diagnostic Substances).
Are there any specific collaboration agreements mentioned in the filing data?
Yes, the filing data mentions 'Second Gilead Common Stock Purchase Agreement', 'Kite Collaboration Agreement and Amendment', and 'Gilead Collaboration Agreement'.
Filing Details
This Form 10-Q (Form 10-Q) was filed with the SEC on May 8, 2025 regarding Arcellx, Inc. (ACLX).